# OPTIMIZE IDE for the Treatment of ACS

> **NCT03190473** · NA · TERMINATED · sponsor: **Svelte Medical Systems, Inc.** · enrollment: 1630 (actual)

## Conditions studied

- Acute Coronary Syndrome

## Interventions

- **DEVICE:** DES

## Key facts

- **NCT ID:** NCT03190473
- **Lead sponsor:** Svelte Medical Systems, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-01-02
- **Primary completion:** 2020-07-17
- **Final completion:** 2023-03-08
- **Target enrollment:** 1630 (ACTUAL)
- **Why stopped:** Company financial insolvency, not due to safety or efficacy concerns
- **Last updated:** 2023-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03190473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03190473, "OPTIMIZE IDE for the Treatment of ACS". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT03190473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*